A6544512
Ozagrel , ≥98% , 82571-53-7
CAS NO.：82571-53-7
Empirical Formula: C13H12N2O2
Molecular Weight: 228.25
MDL number: MFCD00868231
EINECS: 919-112-4
| Pack Size | Price | Stock | Quantity |
| 5G | RMB373.60 | In Stock |
|
| 10MG | RMB479.20 | In Stock |
|
| 50MG | RMB1244.80 | In Stock |
|
| 250MG | RMB3999.20 | In Stock |
|
| others | Enquire |
Update time: 2022-07-08
PRODUCT Properties
| Melting point: | 223-224° |
| Boiling point: | 468.0±25.0 °C(Predicted) |
| Density | 1.17±0.1 g/cm3(Predicted) |
| storage temp. | Sealed in dry,Room Temperature |
| solubility | DMSO : 50 mg/mL (219.06 mM; Need ultrasonic) |
| form | Powder |
| pka | 4.43±0.10(Predicted) |
| color | White to off-white |
| CAS DataBase Reference | 82571-53-7(CAS DataBase Reference) |
Description and Uses
Ozagrel sodium is the first thromboxane (TX2) synthetase inhibitor to be developed as an antithrombotic agent. In patients with angina pectoris, ozagrel sodium reportedly decreases the frequency of anginal attacks and increases exercise tolerance. Other indications for ozagrel sodium currently under study include bronchial asthma and pulmonary thromboembolism.
Ozagrel is a potent and selective thromboxane A2 inhibitor. Used in the prevention of ischemic stroke injury and maintains a strong effect in vascular contraction and vascular endothelial cell dysfunction.
Safety
| Symbol(GHS) |  GHS07 |
| Signal word | Warning |
| Hazard statements | H302 |
| Precautionary statements | P264-P270-P301+P312-P330-P501 |
